Source: Annual Congress 2011 - Treatment options and tumour biology of malignant pleural mesothelioma
Disease area: Thoracic oncology



Rating:

Share or cite this content

Citations should be made in the following way:
A. Diaz-Baquero, B. Romero Romero, L. Gomez-Izquierdo, R. Avila Polo, J. Martin-Juan, F. Rodriguez-Panadero (Seville, Spain). Epithelial-to-mesenchymal transition in malignant mesothelioma. Eur Respir J 2011; 38: Suppl. 55, 2950

Member's Comments

No comment yet.

Related content which might interest you: Multimodality treatment of malignant pleural mesothelioma Source: Annual Congress 2011 - Treatment options and tumour biology of malignant pleural mesothelioma Year: 2011 All-trans-retinoic acid inhibits tumor growth of malignant pleural mesothelioma in mice Source: Annual Congress 2010 - Basic mechanisms in malignant pleural disease biology Year: 2010 Dissecting the mTOR pathway in malignant pleural mesothelioma Source: Annual Congress 2010 - Basic mechanisms in malignant pleural disease biology Year: 2010 Pleural atypical mesothelial hyperplasia: An early stage of pleural malignant mesothelioma? Source: Annual Congress 2012 - Clinical issues in malignant pleural effusions Year: 2012 Effects of mTOR Inhibition in malignant mesothelioma Source: Annual Congress 2010 - Basic mechanisms in malignant pleural disease biology Year: 2010 Indolent lung cancers Source: Annual Congress 2011 - Slow-growing lung cancer Year: 2011 Epithelial mesenchymal transition Source: Research Seminar 2010 - Novel insights in pulmonary fibrogenesis: from bench to bedside Research Seminar Year: 2010 Malignant mesothelioma Source: ERS Skills Course 2018 - Thoracoscopy and pleural techniques Year: 2018 How to develop a pleural service Source: Annual Congress 2011 - PG16 Thoracic ultrasound for physicians Year: 2011 Dealing with diagnosis of benign and malignant pleural effusions Source: Annual Congress 2010 - PG5 Postgraduate Course: Interventional thoracoscopy Year: 2010 Osteopontin of either host or tumor origin critically affects malignant pleural effusion formation Source: Annual Congress 2010 - Basic mechanisms in malignant pleural disease biology Year: 2010 Proliferative intercellular signalling pathway in human malignant mesothelioma cells Source: Annual Congress 2010 - Basic mechanisms in malignant pleural disease biology Year: 2010 Thoracoscopy and malignant pleural mesothelioma Source: ERS Course 2015 Year: 2015 Small-cell lung cancer and mesothelioma: diagnosis and management Source: Annual Congress 2011 - PG10 Management of thoracic tumours in practice: a HERMES basic course Year: 2011 Malignant mesothelioma of pleura Source: Eur Respir J 2002; 20: Suppl. 38, 40s Year: 2002 Bevacizumab-targeted therapy for malignant pleural mesothelioma Source: International Congress 2017 – Malignant pleural effusion management in 2017: a review of recent RCTs Year: 2017 Survival time in patients with malignant pleural mesothelioma Source: Annual Congress 2007 - Rare tumours, risk factors and epidemiology in thoracic oncology Year: 2007 Management of malignant pleural mesothelioma Source: School Course 2014 - Medical Thoracoscopy Year: 2014 Management of malignant pleural mesothelioma Source: Hands-on Course 2013 - Medical Thoracoscopy Year: 2013